In North America, countries such as the US has reported the highest numbers of COVID-19 cases. The pandemic has led to chaotic situation in the healthcare sectors, with excessively increased demand for diagnosing and therapeutic devices in the hospitals. For instance, demand for ventilators, respirators, and in vitro diagnostic (IVD) tests has risen drastically in across North American countries. The demand for personal protective kits has also gone up significantly. The FDA has increased its efforts to support the health of people and has rolled out several guidelines for hospitals and healthcare companies. Companies have also enhanced their research and development activities for diagnostics tests and therapeutic devices. For instance, Thermo Fisher Scientific, F. Hoffmann-La Roche AG, EverlyWell, and Abbott, among others, are ate the forefront of COVID-19 diagnosis kit production. Thermo Fisher Scientific has increased its production to be able to produce 5 million tests per week in April. Likewise, Abbott has received Emergency Use Authorization (EUA) for a point-of-care test that can provide results in minutes.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the metabolomics services market. The North America metabolomics services market is expected to grow at a good CAGR during the forecast period.
Report Attribute | Details |
---|---|
Market size in 2021 | US$ 178.89 Million |
Market Size by 2028 | US$ 685.85 Million |
Global CAGR (2021 - 2028) | 21.2% |
Historical Data | 2019-2020 |
Forecast period | 2022-2028 |
Segments Covered |
By Service Type
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |